|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 401/02 | (2006.01) |
| C07D 471/04 | (2006.01) | ||
| A61K 31/506 | (2006.01) | ||
| A61K 31/437 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3333161 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17194307.9 |
| Date of filing the European patent application | 2012-07-25 | |
| (97) | Date of publication of the European application | 2018-06-13 |
| (45) | Date of publication and mention of the grant of the patent | 2020-02-19 |
| (46) | Date of publication of the claims translation | 2020-05-11 |
| (30) | Number | Date | Country code |
| 201161512061 P | 2011-07-27 | US | |
| 201261591363 P | 2012-01-27 | US |
| (72) |
BUTTERWORTH, Sam, GB
WARD, Richard, Andrew, GB
FINLAY, Maurice, Raymond, Verschoyle, GB
KADAMBAR, Vasantha, Krishna, GB
CHINTAKUNTLA, Chandrasekhara, Reddy, GB
MURUGAN, Andiappan, GB
CHUAQUI, Claudio, Edmundo, US
REDFEARN, Heather, Marie, GB
|
| (73) |
Astrazeneca AB,
151 85 Södertälje,
SE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | 2-(2,4,5-Pakeistieji-anilino)pirimidino dariniai kaip EGFR moduliatoriai, naudingi vėžio gydymui |
| 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER |
| Payment date | Validity (years) | Amount | |
| 2025-06-19 | 14 | 289.00 EUR |
| 2026-07-25 |